Overview
Aleva Neurotherapeutics is a Swiss medical device company developing directional deep brain stimulation leads for Parkinson's disease and other movement disorders. Their directSTIM technology enables highly targeted stimulation to maximize therapeutic benefit while minimizing side effects.
More in Brain-Computer Interfaces
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
🧠 Brain-Computer Interfaces
Location
Lausanne, Switzerland
Funding
Series C · $35M
Website
aleva-neuro.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →